tqb2922

TQB2922 is an investigational antineoplastic drug currently in Phase I clinical trials for the treatment of advanced cancers and neoplasms. It is being developed as an injectable therapy. While the precise mechanism of action has not been publicly disclosed, TQB2922 is reported to be a dual antibody targeting both epidermal growth factor receptor (EGFR) and c-Met (also known as MET), two receptor tyrosine kinases implicated in tumor growth and resistance mechanisms. The drug is being developed by Chia Tai Tianqing Pharmaceutical Group and Nanjing Shunxin Pharmaceutical[3][4][7][8]. The primary aim of ongoing studies is to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy, and immunogenicity in patients with advanced malignancies who have failed standard therapies[1][4].